iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
“Fat” in this 2008 headline means lipid-like carrier molecules—not body fat or an obesity treatment. Researchers called the materials lipidoids and investigated whether they could carry gene-silencing RNA into cells. The work was preclinical: it reported cell and animal experiments, not human trials or an approved treatment.
What does “fat” mean in this gene-silencing story?
It refers to lipidoids: synthetic, lipid-like materials designed to help deliver RNA molecules into cells. RNA can be used to reduce the activity of a selected gene, but it must reach the appropriate cellular machinery to do so. The carrier is meant to help with that delivery problem; it is not itself a gene or a treatment for excess body weight.
In a paper published online on 27 April 2008 in Nature Biotechnology, Akin Akinc and colleagues described a rapid synthesis method and screened a library of more than 1,200 structurally diverse lipidoids. They identified materials that supported specific silencing of endogenous gene transcripts when formulated with small interfering RNA (siRNA) or antisense oligonucleotides aimed at microRNA.
How does RNA interference silence a gene?
siRNA directs the cell to a matching RNA message
Genes are expressed through RNA messages that cells use to make proteins. In RNA interference (RNAi), a short RNA molecule such as siRNA can guide cellular machinery to a matching RNA message, reducing its availability and thereby lowering expression of the targeted gene. The sequence provides the targeting information; delivery is a separate challenge.
#1 Best Overall
The carrier addresses delivery, not target selection
RNA molecules do not automatically reach the right place inside a cell after administration. Lipidoids were investigated as components of formulations that could help RNA enter cells and become active. Their role was to assist delivery of the RNA cargo, while the RNA sequence determined which gene message was targeted.
What did the 2008 experiments show?
The study evaluated lipidoid-based delivery in cell experiments and in mice, rats, and nonhuman primates. The Chemistry World report described experiments using siRNA against factor VII, a blood-clotting factor expressed in the liver; researchers measured the target mRNA in blood and liver tissue. These findings supported further investigation of the delivery approach in animal models, but they do not establish efficacy or safety in people.
The paper’s authors argued that the materials might have broad utility for local and systemic delivery of RNA therapeutics. That was a research prospect, not evidence that every lipidoid could deliver every RNA to every tissue. The report also noted a key limitation: the described materials could not direct delivery to specific cell types. That matters when a therapy must reach one cell population while avoiding others.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →Was this a human treatment?
No human trials are reported in the paper or the 2008 news coverage summarized here. The evidence described is preclinical—cell experiments and animal models—and does not show that this particular method became an approved therapy. Nor does it establish the present-day clinical status of other RNAi delivery technologies or medicines.
The significance of the work is narrower and more useful to understand: it offered a way to rapidly make and screen many lipid-like candidates, then showed that some could support RNA-mediated gene silencing in preclinical tests. Translating such a result into a human treatment would require evidence about delivery to the intended tissue, cell specificity, safety, and clinical benefit.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Why did the researchers’ approach matter?
The library contained more than 1,200 distinct candidates, allowing researchers to examine a broad range of structures rather than rely on a single carrier design. The Chemistry World report quoted researcher Daniel G. Anderson describing a synthesis process in which suitable starting materials could be mixed without solvent or multiple purification and protection steps. That quote describes the reported chemistry workflow; it is not a claim about clinical performance.
The paper appeared in Nature Biotechnology 26, pages 561–569, after online publication on 27 April 2008. Chemistry World published its account on 28 April 2008. Read in that historical context, “gets fat” describes an effort to improve RNA delivery with lipid-like materials—not a clinical breakthrough already available to patients.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Repair Windows errors before they cause bigger problems3Fix the driver behind crashes, sound loss and screen glitchesQuick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
